Shirish Gadgeel

HCRN-LUN17-126

Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients

Status

Closed

Cancer Types

Lung

Locations